Holen Sie sich die Stockscreener-App
1.96
1.01%
-0.02
Handel nachbörslich:
1.83
-0.13
-6.63%
Nextcure Inc Aktie (NXTC) Neueste Nachrichten
NextCure Inc. (NXTC) Q1 2026 Earnings: Narrower Loss Beats Estimates, but Zero Revenue Weighs on Shares - newsline.com
NXTC Q1 2026 Earnings: Narrower Loss Beats Estimates, No Revenue YetEarnings Decline Risk - newsline.com
What's going on with NextCure stock Wednesday? - MSN
NextCure Inc stock (US65343E1082): Pipeline focus after restructuring and cash runway update - AD HOC NEWS
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers - The Manila Times
Cancer experts discuss SIM0505 trial data in on-demand replay - Stock Titan
NextCure Inc. (NXTC) Q1 2026 Earnings: EPS Beat Driven by Lower Operating Costs, Stock Falls on Cash Runway ConcernsRevenue Warning Signal - newsline.com
What's Going On With NextCure Stock Wednesday? - Benzinga
NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous CarcinomaSlideshow (NASDAQ:NXTC) 2026-06-02 - Seeking Alpha
Lucid Capital Maintains NextCure(NXTC.US) With Buy Rating, Maintains Target Price $25 - Moomoo
NextCure Reports 55% Response Rate in Phase 1 SIM0505 Trial for Gynecologic Cancers at ASCO 2026 - Minichart
NextCure Reports Positive SIM0505 Phase 1 Gynecologic Cancer Data - TipRanks
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 - The Manila Times
NextCure presents SIM0505 Phase 1 data: 55% ORR in gynecologic cancers; cash runway into Q1 2027 - TradingView
NextCure reports 55% response rate for SIM0505 in gynecologic cancers - Investing.com
Strong SIM0505 Phase 1 gynecologic cancer data for NextCure (Nasdaq: NXTC) - Stock Titan
Experimental ovarian and uterine cancer drug shows 55% response rate - Stock Titan
NXTC Q1 2026 Earnings: Narrower-Than-Expected Loss Driven by Cost DisciplineProfitability Analysis - The Legal Advocate
NextCure Inc. (NXTC) Surges 5.44% as Shares Test Key ResistanceGap Up Stocks - The Legal Advocate
NXTC - Finviz
NXTC Q1 2026 Earnings: Narrowed Loss Beats Estimates, Stock GainsEarnings Yield Spread - newsline.com
NextCure (NXTC) Plunges Over 22% as Selling Pressure IntensifiesWedge Breakout - The Legal Advocate
NextCure Inc. (NXTC) Q1 2026 Earnings: EPS Beat Amid No Revenue and Steep Stock DeclineEarnings Sentiment Score - The Legal Advocate
NextCure Inc. (NXTC) Gains 5.75% as Biotech Stock Tests Resistance Near $10.71Bollinger Band - Newser
NextCure stock (US65343E1082): biotech shares in focus after China licensing deal for SIM0505 - AD HOC NEWS
NextCure (NXTC) Q1 2026 Earnings: $-1.87 EPS Surges Past $-2.15 EstimatesSocial Buy Zones - Newser
NXTC NextCure earnings beat estimates by 67 percent yet shares retreat despite EPS outperformanceSubscription Growth Report - newsline.com
NextCure stock (US65343E1082): biotech shares react to recent strategic update and Nasdaq trading mo - AD HOC NEWS
SilverArc and Devesh Gandhi report 176,057 shares in NextCure (NXTC) - Stock Titan
TradingKey - TradingKey
Lucid Capital Markets initiates NextCure stock with buy on ADC pipeline By Investing.com - Investing.com South Africa
Lucid Capital Markets initiates NextCure stock with buy on ADC pipeline - Investing.com
NXTC (NextCure) earnings beat estimates by 67 percent, yet shares retreat despite EPS outperformance.Attention Driven Stocks - Newser
How NextCure (NXTC) maintains its competitive edge | Q4 2025: Profit Exceeds ViewsRevenue Inflection Point - Newser
NextCure | 10-Q: Quarterly report - Moomoo
NextCure 1Q Loss/Shr $1.87 >NXTC - Moomoo
NextCure | 10-Q: Q1 2026 Earnings Report - Moomoo
NextCure (NASDAQ: NXTC) narrows loss but warns on going-concern and funding needs - Stock Titan
NextCure | 8-K: NextCure Provides Business Update and Reports First Quarter 2026 Financial Results - Moomoo
FDA Fast Track and narrower loss mark Q1 2026 for NextCure (NASDAQ: NXTC) - Stock Titan
NextCure maps June cancer data, says cash lasts into 2027 - Stock Titan
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results - Weekly Voice
Simcere entities disclose 9.4% stake in NextCure (NXTC) - Stock Titan
NextCure initiates dose optimization study for ovarian cancer drug - Investing.com
NextCure initiates dose optimization study for ovarian cancer drug By Investing.com - Investing.com Nigeria
Biotechnology company NextCure Inc. announced it is accelerating the progress of its R&D projects by expanding its clinical research center network to Canada and Europe. - Bitget
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers - The Manila Times
NextCure moves ovarian cancer drug into dose testing before ASCO - Stock Titan
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):